Oxford BioMedica (LSE: OXB) is a biopharmaceutical company specialising in the development of novel gene-based therapeutics with a focus on the areas of oncology and neurotherapy. The Company was established in 1995 as a spin out from Oxford University, and is listed on the London Stock Exchange.

Oxford BioMedica has core expertise in gene delivery, as well as in-house clinical, regulatory and manufacturing know-how. In oncology, the pipeline includes an immunotherapy and a gene therapy in multiple Phase II trials, and a preclinical targeted antibody therapy in collaboration with Wyeth. In neurotherapy, the Company’s lead product is a gene therapy for Parkinson’s disease, which is expected to enter clinical trials in 2006, and four further preclinical candidates. The Company is underpinned by over 80 patent families, which represent one of the broadest patent estates in the field.

The Company has a staff of approximately 70 split between its main facilities in Oxford and its wholly owned subsidiary, BioMedica Inc, in San Diego, California. Oxford BioMedica has corporate collaborations with Wyeth, Intervet, Viragen, MolMed and Kiadis; and has licensed technology to a number of companies including Merck & Co, Biogen Idec and Pfizer.

Oxford BioMedica’s LentiVector gene delivery technology, based on lentiviruses, is arguably the most potent system currently available for treating a range of diseases, particularly those of the central nervous system. Oxford BioMedica has shown that its lentiviral vectors are able to deliver genes with high efficiency to a variety of both dividing and non-dividing cells, including neurons in the brain.

Oxford BioMedica has three issued US patents and a European patent for its LentiVector technology. These include broad composition of matter claims and methods of production claims for lentiviral vector gene delivery systems of both human and non-human origin. The patents also cover derivatives of lentiviral vector systems that, unlike many versions of lentiviral vectors, have real clinical utility because of their safety.

The Company has established a neurotherapy pipeline of product candidates based on its LentiVector technology, which includes ProSavin^® for Parkinson’s disease, RetinoStat^® for retinopathy, MoNudin^® for motor neuron disease, SMN1-G for spinal muscular atrophy and Innurex^® for nerve repair.